<DOC>
	<DOCNO>NCT01152697</DOCNO>
	<brief_summary>Psychotropic medication cornerstone treatment individual schizophrenia schizoaffective disorder , however rate full partial non-adherence exceed 60 % . Inadequate adherence associate poor outcome relapse , homelessness , hospitalization , increase health care cost . Studies show direct correlation non-adherence rate relapse schizophrenia ; average , non-adherent patient risk relapse 3.7 time great adherent counterpart . A major obstacle good outcome maintenance treatment patient severe mental illness difficulty medication routines on-going basis . For reason , long-acting injectable antipsychotic medication particularly attractive treatment option population schizophrenia schizoaffective disorder , although unlikely medication treatment alone likely modify long-term attitude behavior . This prospective study pilot analysis combine approach merge psychosocial intervention optimize treatment attitude towards psychotropic medication ( CAE ) long-acting injectable antipsychotic medication ( L ) recently homeless individual schizophrenia schizoaffective disorder know on-going difficulty treatment non-adherence . It expect combined approach ( CAE-L ) improve illness outcome among vulnerable population schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic</brief_title>
	<detailed_description />
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Individuals age 18 year old old schizophrenia schizoaffective disorder confirm Mini International Psychiatric Inventory ( MINI ) . 2 . Individuals currently recently homeless ( within past 12 month ) per official federal definition homelessness . 3 . Known medication treatment adherence ( 20 % missed medication past week past month ) problem identify Treatment Routines Questionnaire patient clinician version ( TRQP/TRQC ) . 4 . Ability rat psychiatric rating scale . 5 . Willingness take longacting injectable medication . 6 . Currently receive treatment Community Mental Health Clinic ( CMHC ) another mental health treatment provider able provide continuity care study participation . 7 . Able provide write , inform consent study participation . 8 . Women childbearing potential must utilize reliable , medicallyaccepted method birth control . 1 . Known resistance intolerance haloperidol haloperidol decanoate . 2 . Medical contraindication haloperidol haloperidol decanoate . 3 . Individuals longacting injectable antipsychotic medication immediately prior study enrollment . 4 . Prior current treatment clozapine . 5 . Concurrent medical condition psychiatric illness , opinion research psychiatrist , would interfere patient 's ability participate trial . 6 . Current substance dependence . 7 . High risk harm self others . 8 . Female currently pregnant breastfeed . 9 . Individual already permanent support housing include comprehensive mental health service ( e.g . Housing First ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>nonadherence</keyword>
	<keyword>noncompliance</keyword>
	<keyword>homeless</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective</keyword>
</DOC>